Related Experiment Video

Updated: May 29, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

The LOX-1 3'UTR188CT polymorphism and coronary artery disease in Turkish patients

Ozlem Kurnaz1, A Başak Akadam-Teker, Hülya Yilmaz-Aydoğan

  • 1Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Capa, 34390, Istanbul, Turkey.

Molecular Biology Reports
|September 9, 2011
PubMed

Insights

The lectin-like oxidized low-density lipoproteins receptor-1 (LOX-1) 3'UTR188CT gene variation may increase the risk of left ventricular hypertrophy (LVH) in coronary artery disease (CAD) patients, particularly when associated with elevated blood pressure.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetic Epidemiology

Background:

  • Left ventricular hypertrophy (LVH) is a significant risk factor for cardiac death in coronary artery disease (CAD).
  • The lectin-like oxidized low-density lipoproteins receptor-1 (LOX-1) gene's 3'untranslated region (3'UTR) 188CT polymorphism has been linked to increased CAD risk.
  • Understanding genetic predispositions to LVH in CAD patients is crucial for risk stratification.

Purpose of the Study:

  • To investigate the association between the LOX-1 3'UTR188CT gene polymorphism and the development of LVH in a Turkish population with CAD.
  • To determine if this specific genetic variation influences cardiovascular risk factors in CAD patients.

Main Methods:

  • A population-based case-control study was conducted.
  • 83 CAD patients and 99 healthy controls were genotyped for the LOX-1 3'UTR188CT polymorphism using PCR-RFLP.
  • Genotypes were analyzed for associations with LVH and lipid profiles.

Main Results:

  • The LOX-1 3'UTR188 TT genotype was significantly associated with increased systolic blood pressure (P=0.047) and a higher risk of LVH (P=0.014, OR: 3.541) compared to C allele carriers.
  • In control subjects, the TT genotype correlated with decreased HDL-cholesterol (P=0.031).
  • In CAD patients, the TT genotype was linked to increased VLDL-cholesterol (P=0.009).

Conclusions:

  • The LOX-1 3'UTR188CT gene polymorphism may contribute to the development of LVH in CAD patients.
  • This predisposition appears to be dependent on blood pressure levels.
  • The findings highlight the role of specific genetic variations in modulating cardiovascular disease phenotypes.

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...